IRVINE, Calif., June 23, 2014 /PRNewswire/ -- Central Admixture Pharmacy Services, Inc. (CAPS®) announced that its San Diego location has registered with the FDA as a 503B Outsourcing Facility. CAPS San Diego joins CAPS Lehigh Valley as the second CAPS facility registered under section 503B of the Drug Quality and Security Act (DQSA) as an Outsourcing Facility for anticipatory compounding. The law modified the Federal Food Drug and Cosmetic Act (FFDCA) by creating the new section 503B class of registrant as well as clarifying how "traditional pharmacy compounders" will be regulated under section 503A of the FFDCA.
"As a voluntary FDA registrant for more than two decades, CAPS will continue to provide the highest quality outsourced sterile compounded preparations under the new registration category," said Tom Wilverding, President of CAPS.
With 25 locations nationwide, CAPS® provides unparalleled customer service, including same day delivery to hospital pharmacies, oncology clinics, surgery centers and long-term care facilities. As a market leader in outsourced Parenteral Nutrition (PN), CAPS® offers customized PN, hydration, chemotherapy and additional services for pediatric and adult patients across the country. Through its FDA registered 503B outsourcing facilities, CAPS offers a complete catalogue of anticipatory compounded controlled substances, anesthesia drugs, post-op pain pumps, and many other solutions.
Consider CAPS for your compounding needs. To learn more, visit CAPSpharmacy.com.
SOURCE Central Admixture Pharmacy Services, Inc. (CAPS), a B. Braun company